have covered various indications, mostly commonly psychiatric disorders (7 letters), pain (5 letters), and cancer (4 letters). No DDMAC letter pertained to FDAMA Section 114. CONCLUSIONS: The FDA continues to regulate health economic promotions and express concern about certain inappropriate practices, particularly unsupported work productivity claims and hidden clinical claims (i.e., about effectiveness or safety) embedded in health economic information. More guidance from the Agency would help clarify what level of substantiation is required for health economic promotions.
OBJECTIVES: Assessment of lost productivity through health-related productivity instruments (HRPIs) is useful for pharmacoeconomic research. The aim of this study was to conduct a systematic review and critique of HRPIs. METHODS: Through a comprehensive search in the PubMed database using the keywords "health-related productivity," "absenteeism," and "presenteeism," the following generic, validated HRPIs were found: American Productivity Audit and Work Health Interview (APA&WHI), Endicott Work Productivity Scale (EWPS), Health and Labor Questionnaire (HLQ), Health and Work Performance Questionnaire (HPQ), Health and Work Questionnaire (HWQ), Health-Related Productivity Questionnaire-Diary (HRPQ-D), Stanford Presenteeism Scale (SPS), Work Limitations Questionnaire (WLQ), Work Productivity and Activity Impairment (WPAI), Work Productivity Short Inventory (WPSI), and Worker Productivity Index (WPI). All HRPIs were graded on five major and three minor assessment criteria. Major criteria included (1) lost productivity could be attributed to a specific health-problem; (2) presenteeism was measured; (3) absenteeism was measured; (4) lost productivity was expressed in hours lost; and (5) productivity could be measured for both those in and out of the labor force. Minor criteria included (1) how perceived impairment was measured; (2) the minimum recall period required; and (3) whether population norms existed or could be obtained. RESULTS: All of the HRPIs except HRPQ-D failed to provide information on at least one major criterion. The SPS, WLQ, WPAI and WPSI lacked information on 1 major criterion, APA&WHI, HLQ and HPQ on 2 major criteria, EWPS on 3 major criteria and HWQ on 4 major criteria. The HRPQ-D, SPS, WLQ, WPAI and WPSI satisfied all or at least 1 major criterion but lacked 1-3 minor criteria. The common major criterion frequently lacking among the SPS, WLQ, WPAI and WPSI was either household-related productivity loss or valuation. CONCLUSIONS: Current HRPIs lack comprehensive estimation of lost productivity. There is an opportunity to develop stronger survey instruments.
PR4 BREAST CANCER MORTALITY RATES BY GEOGRAPHIC REGION, YEARS OF POTENTIAL LIFE LOST, AND VALUE OF PRODUCTIVITY LOSSES AMONG WOMEN AGED 20-49 YEARS IN THE UNITED STATES, 1970 -2008
Ekwueme DU, Guy GP, Rim SH, Hall IJ, Thomas CC, Fairley TL, Rodriguez J, White A Centers for Disease Control and Prevention, Atlanta, GA, USA OBJECTIVES: There are no studies in the United States examining the trends in mortality rates, years of potential life lost (YPLL), and value of productivity losses due to breast cancer (BC) among women aged 20-49 years. We examined the trends in BC mortality rates by geographic region, estimated YPLL and value of productivity losses by race/ethnicity. METHODS: National mortality data from 1970-2008 were used to calculate age-adjusted mortality rates and rate ratios (RRs). Joinpoint regression analysis was used to assess changes in trends over time. The YPLL were calculated to quantify the burden of premature mortality. The value of lost lifetime productivity earnings of young women who died of BC in 2008 were used to quantify the expected future value of lost productivity due to premature mortality. RESULTS: From 1970 through 2008 the age-adjusted mortality rate from BC among white young women was 11.45/100,000 and 17.97/100,000 among blacks. Compared with whites, blacks had substantial higher age-adjusted breast cancer mortality rates. BC mortality rates vary by geographic region. The decline in BC mortality rates among blacks has been small (-0.68% per year) compared with whites (-2.02% per year). During the same period, the total number of deaths associated with BC in young women was 225,866, which accounted for an estimated 7.98 million YPLL. The estimated total productivity losses attributed to BC in young women who died in 2008 was $5.49 billion. On average, a young woman who died from BC in 2008 would lose $1.10 million in forgone lifetime earnings. CONCLUSIONS: Although blacks have substantially higher age-adjusted BC mortality rates, there has been very little overall change in death rates over time compared to other races. Our results may implicate the need for focused attention to racial disparities in BC diagnosis, treatment, and survivorship efforts among specific populations.
PODIUM SESSION III: RESEARCH ON MEDICAL OUTCOMES QUESTIONNAIRES

QU1 THE DEVELOPMENT AND VALIDATION OF A REVISED VERSION OF THE MEDICAL OUTCOMES STUDY SLEEP SCALE (MOS-SLEEP-R)
Yarlas AS, White MK, Smith KJ, Bjorner JB QualityMetric Incorporated, Lincoln, RI, USA
OBJECTIVES: To develop a revised version of the Medical Outcomes Study Sleep
Scale (MOS-Sleep-R), and to evaluate its psychometric properties within a representative sample of US adults. METHODS: The MOS-Sleep, developed in the late 1980s, is a 12-item patient-reported instrument measuring sleep outcomes over the previous 4 weeks, yielding six domain scores -Disturbance, Adequacy, Somnolence, Snoring, Awakening to due to shortness of breath/headache, and Quantity -and two global Sleep Problem Indices (SPI). The MOS-Sleep-R implemented the following changes: the response option "a good bit of the time" was removed; a 1-week recall period form was introduced; and 0-100 scores were replaced by standardized T-scores (meanϭ50, standard deviationϭ10 in the US general population) with higher scores reflecting better sleep outcomes. Standardization was based on data from a 2009 US internet-based general population survey. The psychometric properties of both 1-week and 4-week recall forms of the MOS-Sleep-R were examined within this development sample. RESULTS: The 1-week and 4-week recall forms of the MOS-Sleep-R were completed by 2045 and 2033 respondents, respectively. The psychometric properties of the 1-week and 4-week forms were similar. Patterns of inter-item and item-scale correlations support the scaling assumptions of the instrument. All multi-item domains, global index scores, and the total scales showed adequate internal consistency reliability (all Cronbach's ␣ Ͼ 0.75). Patterns of correlations between MOS-Sleep-R scores with criterion measures of quality of life, psychological state, and work and health outcomes indicated adequate convergent validity. Differences in mean scores across groups that differed on the criterion outcomes supported the instrument's discriminant validity. CONCLUSIONS: The MOS-Sleep-R introduces a number of improvements, including simplified response sets, the introduction of a 1-week recall form, and normbased scoring that enhances interpretability of scores. Both the 1-week and 4-week recall period forms of the MOS-Sleep-R demonstrated good reliability and validity. -5) . This report furthers the initial validation conducted in the United States by evaluating the reproducibility and construct validity outside the United States. METHODS: The ENSEMBLE MDS and other assessments (MOS SF-36, EQ-5D, Life Orientation Test-Revised (LOT-R), items on illness/bed days and doctor visits) were administered to a sample of adults with depression, type 2 diabetes, or rheumatoid arthritis in Germany (nϭ61), Spain (nϭ61) and Singapore (nϭ56, Simplified Chinese). Participants completed the battery on paper and returned one-week later to complete a retest. Test-retest reproducibility was assessed using the intraclass correlation coefficient (ICC); convergent validity by Pearson correlations between MDS instruments and components of the SF-36 and EQ-5D, with hypothesized relationships significant at rϾ0.30; and known-groups tested using tertiles of the LOT-R, doctor visits and illness days. RESULTS: The mean age of the participants was 55Ϯ13 years, 63% were female, 66% were married/living with partner. Between 85% and 100% completed MDS instruments at the retest (mean 6.7Ϯ0.6 days). The ICCs for A11 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
QU2
CROSS-CULTURAL PSYCHOMETRIC EVALUATION OF THE ENSEMBLE MDS
